BioWorld

May 3, 2004

Sirna, Immune Response Pad Coffers With Private Placements

Genta, Allos Both Hurt By FDA Briefing Documents

Two firms scheduled to go before the Oncologic Drugs Advisory panel today took painful financial hits on Friday when FDA reviewers released unfavorable comments about their respective cancer treatments. (BioWorld Today) Read More

Biogen Idec Earnings Strong At Year's 'High-Water Mark'

Post-Meal Glucose Hangs Up Aradigm's Diabetes Treatment

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 21, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...